Literature DB >> 29487960

[Topical therapy for atopic eczema].

M Knop1, A Gürtler1, A Heratizadeh2, N Aszodi1, Th Werfel2, A Wollenberg3.   

Abstract

Atopic eczema is a chronic recurrent inflammatory skin disease characterized by intensive pruritus and a high burden of disease. Based on a genetically determined skin barrier dysfunction, xerosis cutis and a tendency towards microbial skin infections are the leading clinical features. Mild and moderate disease manifestations are common, and usually treated with topical agents only. Treatment concepts are usually based on a combination of (i) topical basic therapy consisting of skin cleansing and barrier stabilizing emollients and (ii) topical anti-inflammatory therapy of visible skin lesions with topical corticosteroids and topical calcineurin inhibitors. Proactive therapy of the commonly affected and usually relapsing areas of skin is an important therapeutic option for long-term maintenance treatment of moderate to severe disease. Patients should be actively involved in planning of treatment, which should be adapted to individual patient factors such as age, involved body areas, type of skin lesions, as well as seasonal and climatic factors. New promising treatment options including topical phosphodiesterase inhibitors and topical Janus kinase inhibitors are currently being evaluated in clinical trials and may become a future treatment option for atopic eczema. This review article summarizes the current topical treatment options and new perspectives in the topical therapy of atopic eczema.

Entities:  

Keywords:  Calcineurin inhibitors; Corticosteroids; Janus kinase inhibitors; Patient involvement; Phosphodiesterase inhibitors

Mesh:

Substances:

Year:  2018        PMID: 29487960     DOI: 10.1007/s00105-018-4135-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  54 in total

1.  The structure of normal skin and the morphology of atopic eczema.

Authors:  M C Mihm; N A Soter; H F Dvorak; K F Austen
Journal:  J Invest Dermatol       Date:  1976-09       Impact factor: 8.551

2.  Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Authors:  Amy S Paller; Wynnis L Tom; Mark G Lebwohl; Robin L Blumenthal; Mark Boguniewicz; Robert S Call; Lawrence F Eichenfield; Douglass W Forsha; William C Rees; Eric L Simpson; Mary C Spellman; Linda F Stein Gold; Andrea L Zaenglein; Matilda H Hughes; Lee T Zane; Adelaide A Hebert
Journal:  J Am Acad Dermatol       Date:  2016-07-11       Impact factor: 11.527

Review 3.  Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis.

Authors:  Noreen Heer Nicol; Mark Boguniewicz
Journal:  Immunol Allergy Clin North Am       Date:  2016-11-01       Impact factor: 3.479

4.  A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.

Authors:  Linda F Stein Gold; Lynda Spelman; Mary C Spellman; Matilda H Hughes; Lee T Zane
Journal:  J Drugs Dermatol       Date:  2015-12       Impact factor: 2.114

5.  Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.

Authors:  A Wollenberg; M K Sidhu; I Odeyemi; B Dorsch; R Koehne-Volland; M Schaff; B Ehlken; K Berger
Journal:  Br J Dermatol       Date:  2008-09-06       Impact factor: 9.302

Review 6.  Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background.

Authors:  Andreas Wollenberg; Reiner Frank; Julia Kroth; Thomas Ruzicka
Journal:  J Dtsch Dermatol Ges       Date:  2008-08-07       Impact factor: 5.584

Review 7.  Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting.

Authors:  U Blume-Peytavi; M J Cork; J Faergemann; J Szczapa; F Vanaclocha; C Gelmetti
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-07       Impact factor: 6.166

Review 8.  Atopic dermatitis - all you can do from the outside.

Authors:  C Gelmetti; A Wollenberg
Journal:  Br J Dermatol       Date:  2014-05-09       Impact factor: 9.302

9.  Anti-inflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models.

Authors:  Marie-Françoise Aries; Hélène Hernandez-Pigeon; Clémence Vaissière; Hélène Delga; Antony Caruana; Marguerite Lévêque; Muriel Bourrain; Katia Ravard Helffer; Bertrand Chol; Thien Nguyen; Sandrine Bessou-Touya; Nathalie Castex-Rizzi
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-11-10

Review 10.  Current aspects of innate and adaptive immunity in atopic dermatitis.

Authors:  Andreas Wollenberg; Elisabeth Klein
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817

View more
  1 in total

1.  [Atopic eczema].

Authors:  A Wollenberg; T Biedermann
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.